质子束放疗对比射频消融治疗复发性肝细胞癌:一项随机III期试验
这项III期非劣效性随机试验比较质子束放疗(PBT)与射频消融(RFA)治疗复发性/残留性小肝细胞癌(rHCC)的效果。在意向治疗人群(ITT)中,PBT组与RFA组的2年局部无进展生存率(LPFS)分别为92.8%和83.2%,差异为9.6个百分点(90%CI 0.7-18.4;p<0.001),符合非劣效性标准。PBT耐受性良好且安全。
要点
- 在ITT人群中,PBT组2年LPFS率为92.8%,RFA组为83.2%,差异9.6个百分点(90%CI 0.7-18.4),达到非劣效性。
- 在符合方案人群中,PBT组2年LPFS率为94.8%,RFA组为83.9%,差异10.9个百分点(90%CI 1.8-20.0)。
- PBT组最常见不良事件为放射性肺炎(32.5%)和白细胞计数下降(23.8%);RFA组为丙氨酸氨基转移酶升高(96.4%)和腹痛(30.4%)。
核心结论
- PBT的LPFS不劣于RFA,且PBT耐受性良好且安全。
研究设计与样本
- III期非劣效性随机对照试验,纳入复发性/残留性肝细胞癌(rHCC)患者(肿瘤大小<3 cm,数目≤2个),按Child-Pugh评分和肿瘤分期随机分配至PBT或RFA组。
- ITT人群共144例,PBT组72例,RFA组72例;PP人群PBT组80例,RFA组56例。
- 主要终点为2年局部无进展生存率(LPFS),非劣效界值为15%,在PP人群中进行主要分析,并在ITT人群中进行补充分析(NCT01963429)。
主要发现
- 在PP人群中,PBT组(n=80)2年LPFS率为94.8%,RFA组(n=56)为83.9%,差异为10.9个百分点(90%CI 1.8-20.0;p<0.001)。
- 在ITT人群中,PBT组2年LPFS率为92.8%,RFA组为83.2%,差异为9.6个百分点(90%CI 0.7-18.4;p<0.001),满足非劣效性标准。
- PBT的3年和4年LPFS率也非劣于RFA。
- PBT组最常见不良事件为放射性肺炎(32.5%)和白细胞计数下降(23.8%);RFA组为丙氨酸氨基转移酶升高(96.4%)和腹痛(30.4%)。
- 未观察到4级不良事件或死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Proton beam radiotherapy (PBT) has recently been applied to treat hepatocellular carcinoma (HCC); however, there is no randomized controlled trial-based evidence on its safety and efficacy. We compared the outcomes of PBT and radiofrequency ablation (RFA) in patients with recurrent/residual HCC (rHCC) in a phase III non-inferiority trial. METHODS: Patients with rHCC (size <3 cm, number ≤2) were randomly assigned to receive PBT or RFA according to Child-Pugh score and tumor stage. After randomization, if the assigned treatment was technically infeasible, crossover was allowed. The primary endpoint was 2-year local progression-free survival (LPFS), with a non-inferiority margin of 15% in the per-protocol (PP) population; a complementary analysis was performed in the intention-to-treat (ITT) population (NCT01963429). RESULTS: The ITT population comprised 144 patients receiving either PBT (n = 72) or RFA (n = 72). Six patients switched from the PBT arm to the RFA arm and 19 patients switched from the RFA arm to the PBT arm. In the PP population, the 2-year LPFS rate with PBT (n = 80) vs. RFA (n = 56) was 94.8% vs. 83.9%, a difference of 10.9 percentage points (90% CI 1.8-20.0; p <0.001); in the ITT population, the 2-year LPFS rate with PBT vs. RFA was 92.8% vs. 83.2%, a difference of 9.6 percentage points (90% CI 0.7-18.4; p <0.001), meeting the criteria for non-inferiority. The 3- and 4-year LPFS rates for PBT were also non-inferior to those for RFA. The most common adverse events were radiation pneumonitis (32.5%) and decreased leukocyte counts (23.8%) for PBT and increased alanine aminotransferase levels (96.4%) and abdominal pain (30.4%) for RFA. No Grade 4 adverse events or mortality were noted. CONCLUSIONS: PBT showed LPFS values that were non-inferior to those for RFA; in addition, PBT was tolerable and safe. CLINICAL TRIAL NUMBER: #NCT01963429 (ClinicalTrials.gov). LAY SUMMARY: Radiofrequency ablation is the standard of care for patients with small hepatocellular carcinoma in whom surgery is not feasible. This study is the first phase III randomized controlled trial to evaluate the clinical outcomes of proton beam radiotherapy vs. radiofrequency ablation in patients with recurrent small HCC. Our findings show that this new technique is not inferior and can be applied safely in patients with small recurrent hepatocellular carcinoma.
引用
- Kim TH, Koh YH, Kim BH, et al. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. J Hepatol. 2020. PMID: 33031846. doi:10.1016/j.jhep.2020.09.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。